关键词: 利奈唑胺, 耐甲氧西林金葡菌（MRSA）, 血小板减少

Abstract:

AIM: To evaluate the clinical rationality, efficacy and safety of linezolid in our hospital in 2016 and to provide reference for its clinical application. METHODS: A retrospective study was conducted using the medical history data of patients treated with linezolid in 2016. The questionnaire was designed to compile statistics of rational use rate, to analyze the causes of irrational use, and to calculate the clinical cure rate, pathogen clearance rate and comprehensive cure rate, as well as to monitor the red blood cell, hemoglobin and platelet decline after treatment of linezolid. RESULTS: The rational use rate of linezolid was 48.1%, the irrational reasons are mainly that the indication was unreasonable and the course of treatment was unreasonable. The clinical cure rate was 40.4%, the pathogen clearance rate was 42.3%, and the comprehensive cure rate was 56.4%. The incidence of myelosuppression was 21.2% in patients whose average age was （81.4±8.7）years old, and the average course of treatment was （13.6±5.6）days. CONCLUSION: The rate of clinical rational use of linezolid needs to be improved in our hospital. The correct indication and course of treatment will improve the rational rate to a great extent. And the comprehensive curative effect is acceptable. But special attention should be paid to the occurrence of myelosuppression for the elderly patients.

Key words: linezolid, methicillin resistant Staphylococcus aureus (MRSA), thrombocytopenia